Search...
Benitec Biopharma Releases First Quarter 2026 Financial Results and Provides Operational Update
-Fast Track Designation was granted for BB-301 following U.S. Food and Drug Administration ( FDA ) review of positive interim clinical study results and proprietary Responder Analysis planned for use in pivotal study for ...
Source: GlobeNewswire The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments